{
    "nctId": "NCT01907230",
    "officialTitle": "Propylactic Use of Entecavir for Biological Agents Associated Hepatitis B Virus Reactivation in Inflammatory Arthritis Patients: a Randomized Controlled Trial",
    "inclusionCriteria": "1. Age : from 20 to 90 y/o.\n2. HBsAg-positive for more than 6 months and HBV DNA \\< 2000 IU/ml (Subgroup 1\uff09or HBsAg-negative but anti-HBc positive with HBV DNA \\< 2000 IU/ml (Subgroup 2\uff09.\n3. Inflammatory arthritis patients who plan to treat with biological agents, including Humira or Enbrel or Simponi or Orencia or Mabthera or Actemra; as first line biologic treatment is indicated.\n* Must have minimum age of 20 Years\n* Must have maximum age of 90 Years",
    "exclusionCriteria": "1. HCV, HIV, or HDV coinfection.\n2. Uncontrolled HCC or other malignancy within 3 years.\n3. Decompensated liver cirrhosis (CTP score \u2265 7).\n4. Uremia patients under hemodialysis or continuous ambulatory peritoneal dialysis or patients with Ccr \\< 50 mL/min\n5. Pregnant or breastfeeding women.\n6. Women of child-bearing potential (WOCBP) who are unwilling or unable to use an acceptable method of contraception to avoid pregnancy throughout the study and for up to 4 weeks after the last dose of study drug."
}